Search USGSSearch

Geology topics

Steven Volker

Publications and source records attributed to Steven Volker.

2 recordsLinked to original sources

Toxicity of anticoagulant rodenticides on Pacific salmon: Assessing lethal and sublethal effects

To restore native biodiversity on island ecosystems containing invasive rodents, partial- and whole-island eradications generally rely on broadcast baiting with anticoagulant rodenticides (ARs). This approach can result in bait pellets entering aquatic environments, raising concerns about effects to non-target fish. Salmonids are a dominant group of fishes on many temperate islands targeted for rodent eradication, and AR toxicity data for salmonids are limited. Our goal was to determine if coho salmon ( Oncorhynchus kisutch ) are susceptible to coagulopathy and death via exposure to commonly used ARs. We assessed risk of ARs to coho using dose-response curves generated through intraperitoneal injections after determining that coho would not directly ingest the AR baits. Median lethal doses (96-h LD 50 ) estimated using 100 % corn oil carrier were 85.7 µg/g for brodifacoum and 54.0 µg/g for diphacinone. Acetone (30–41 %), used to dissolve ARs in corn oil, reduced the toxicity of diphacinone (LD 50 = 102.3 µg/g, p < 0.001) but not brodifacoum (LD 50 = 73.3 µg/g, p = 0.126) indicating that solvent choice can influence toxicity outcomes. Behavioral changes and onset of mortality differed between the two ARs, with diphacinone acting more rapidly. Tissue analysis supported a difference in toxicokinetics between the two ARs, with significant decreases in liver and muscle residues for diphacinone but not brodifacoum. Sublethal brodifacoum exposure (53.9 µg/g; LD 13 ) impaired blood clotting at 72- and 96- h but returned to baseline by 120 h. No clotting impairment was observed up to 144 h after diphacinone exposure (45.5 µg/g; LD 4 ), suggesting a non-coagulopathy mode of action. These findings will inform risk assessments when considering use of these ARs for rodent management near streams and shorelines and clearly demonstrate that brodifacoum causes coagulopathy in coho.

Ecotoxciology and Environmental Safety

Preliminary evidence of anticoagulant rodenticide exposure in American kestrels (Falco sparverius) in the western United States

Although there is extensive evidence of declines in the American Kestrel ( Falco sparverius ) population across North America, the cause of such declines remains a mystery. One hypothesized driver of decline is anticoagulant rodenticide (AR) exposure, which could potentially cause mortality or reduced fitness. We investigated AR exposure in wild American Kestrels in Utah, USA. We collected and tested for AR residues in liver samples ( n = 8) from kestrels opportunistically encountered dead and in blood samples ( n = 71) from live wild kestrels, both nestlings and adults. We found high detection rates in both tissues. Adult kestrels were more likely to exhibit exposure than juveniles sampled in nests. Three-quarters (six of eight) of tested liver samples from adult kestrels exhibited evidence of AR exposure. Additionally, liver samples ( n = 19) opportunistically collected from seven species of raptors within our study area had detectable levels of AR residues, with seven of eight raptor species evidencing exposure; across all raptors, five ARs were detected in liver samples, with brodifacoum the most prevalent, being found in over half (14 of 27) of samples. Over half (7 of 12) of the blood samples from adult kestrels had detectible levels of ARs, while only one of 59 juvenile nest samples tested positive. The difference in exposure rates between adults and juveniles could indicate differential exposure pathways by age class. Based on these findings, we recommend that ARs be further investigated as a potential cause of kestrel declines. Future research could focus on expanding sampling to provide sufficient sample sizes to test for potential nonlethal effects of AR exposure (e.g., fecundity, nesting success), identifying potential exposure pathways, and developing methods for passive sampling of ARs in excreta.

Utah